Wednesday, 20 August 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 20 August 2025
News

Viatris gives supply heads-up

Posted 19 August 2025 PM

Supply constraints of Viatris’ PBS listed pancreatic enzyme supplement Creon are expected to hit Australia this month and continue throughout year.

The US headquartered pharmaceutical company created from the merger of Mylan and Upjohn in 2020, has notified the TGA that it anticipates supply constraints related to Creon 25,000 unit and Creon 35,000 unit capsules between 21 August and 31 December 2025 due to an “unexpected global increase in demand”.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.